TP53 and ovarian carcinoma: Ma et al. screened 154 AABs and reported that an optimized panel of anti-TP53, anti-guanine nucleotide-binding protein (GNAS), and anti-nucleophosmin 1 (NPM1) AABs could discriminate ovarian cancer patients from healthy patients with a sensitivity of 51.2%, a specificity of 86.0%, and an accuracy of 68.6% [102].